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DISSERTATION ABSTRACT 
Optimal antiretroviral treatment (ART) adherence is critical in achieving virologic 
suppression.  Most people living with HIV (PLWH) experience HIV-related challenges 
which may be compounded by the experience of stressful life events (SLE) with adverse 
effects on their ART adherence and therefore affecting viral suppression.  The highest 
concentration of people living with HIV (PLWH) is in low-and-middle income countries 
(LMIC) which are challenged with high rates of poverty and unemployment.  Limited 
published data is available on the impact of the stressful life events experienced by PLWH in 
LMIC on ART adherence and viral load. 
A secondary analysis was conducted using data collected in a randomised control trial (RCT) 
which investigated the impact of a real-time electronic adherence monitoring device (EAMD) 
on ART adherence in ART-naïve individuals to assess the impact of SLE on ART adherence 
and viral load. 
Part A of this dissertation includes the study proposal/ protocol as approved by the 
Departmental Research Committee and the Human Research Committee at the University of 
Cape Town.   
Part B details the literature review which examined all published studies which report on 
stressful life events in PLWH, with ART adherence or a viral load as an outcome.  The 
review included published literature from 2008 to 2019. 
Part C includes the publish-ready manuscript which details the statistical analysis, results and 
interpretation of the secondary analysis of impact of SLEs on ART adherence and viral load 
among 200 individuals living with HIV. 
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Part D, appendices were included as supporting documentation necessary for the conduct of 
this research and as required for the completion of this dissertation. 
 
The American Psychological Association (APA) 6th Edition referencing style was used for 
Part A and B.  The Vancouver referencing style was used for Part C as per the instructions for 
authors by the Aids and Behaviour journal guidelines. 
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LIST OF ABBREVIATIONS 
ART: Antiretroviral therapy/ treatment 
aOR:   adjusted odds ratio 
EAMD:  Electronic Adherence Monitoring Device 
HCTC: Hannan Crusaid Treatment Centre, Gugulethu 
HIC:  High income country 
HIV: Human Immunodeficiency Virus 
HP-PC:  Health Provider pill count 
IQR:  Inter quantile range 
LMIC: Low-and-middle income country 
LTFU:  Loss to follow-up 
OR:   Odds ratio 
PR:      Pharmacy refill 
RCT: Randomised Controlled Trial 
SD:  Standard deviation 
SLE:   Stressful life event 
SR: Self-reporting 
TAP study: A randomised controlled Trial to explore Adherence-failure relationships in a 
South African antiretroviral delivery site using an electronic adherence device and 
sparse Pharmacokinetic sampling 
TDM: Therapeutic Drug Monitoring 
USA:   United States of America 
UTPC:   Unannounced telephonic pill count 
VF:   Virologic failure 
VL: Viral load 
WHO: World Health Organisation 
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Title:  The impact of stressful life events on adherence and viral suppression among ART 
naïve individuals 
 
Background and rationale 
The introduction of highly active antiretroviral therapy (HAART) more than two decades ago 
has significantly reduced the mortality and morbidity rates of people living with HIV 
(PLWH).  Generally, PLWH are experiencing better physical health and improved life 
expectancy that are approaching that of the general population.  However, these benefits are 
largely dependent on effective viral suppression which require almost flawless adherence to 
antiretroviral treatment (ART).  Life-long ART requires life-long adherence. 
Previous research has demonstrated that non-adherence to ART is a strong predictor of 
virologic failure.  Virologic failure has life-threatening consequences such as opportunistic 
infections, disease progression, drug resistance and death.   
PLWH are largely concentrated in disadvantaged communities and frequently experience a 
high degree of stressful life events such as interpersonal violence, injuries, serious illness, 
housing instability, high levels of crime, difficulties in relationships, finances and 
employment and death.  These stressful life events are associated with missed pills and 
follow-up appointments.   
Therefore, the experience of stressful life events by PLWH can be identified as a barrier to 
ART adherence. 
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Aim 
This study aims to investigate the impact of stressful life events such as difficulties in health, 
relationships, work, housing, birth, crime and death experienced by ART naïve individuals 
over a 48-week period; on their adherence to antiretroviral treatment and virologic 
suppression.  Cumulative adherence was calculated at week 48 “using 3-day self-report (SR), 
clinic-based pill count (CPC), average adherence by pharmacy refill (PR-average), 
calculation of medication-free days (PR-gaps), efavirenz therapeutic drug monitoring (TDM) 
and an electronic adherence monitoring device (EAMD)” (Orrell et al., 2017, p.1).   
 
Objectives  
1. To describe the type, frequency and duration of the life events experienced by PLWH. 
2. To investigate the impact of stressful life events on antiretroviral treatment adherence and 
viral load. 
 
Methods and population 
This secondary analysis will use retrospective data collected in a randomised control trial 
(RCT) which investigated the impact of a real-time electronic adherence monitoring device 
(EAMD) on antiretroviral treatment (ART) adherence in ART-naïve individuals over a 48- 
week period from 2012 to 2014.  230 HIV-infected individuals, both male and female, 
participated in this study and attended the Hannan Crusaid Treatment Centre (HCTC) in 
Gugulethu, Cape Town.  HCTC is a large community-based ART clinic. 
The eligibility criteria for the RCT included (1) ART-naive individuals aged ≥15 years old 
who commenced ART at HCTC; (2) who owned mobile phones; and (3) were able to give 
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written consent or assent for participants who were ≤18 years old.  Participation was offered 
to all eligible participants who attended the clinic between July 2012 and March 2013. 
A Recent Life Event (RLE) questionnaire was administered at week 48 to investigate the 
contribution of life events to poor ART adherence.  The RLE questionnaire included 19 
questions on life events in categories such health, death, relationships, work, crime, birth, 
housing and other life events not mentioned in other categories.   
The association between life events and ART adherence and viral load will be determined 
using logistic regression models to adjust to other covariates that may influence adherence 
and viral suppression. 
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2. BACKGROUND 
2.1 The disease burden of Human Immunodeficiency Virus (HIV) 
 
The recent 2017 global HIV statistics revealed that HIV continue to be a public health 
priority (Avert, 2018).  Globally, an estimated 36.9 million people were living with HIV 
which includes an estimated 1.8 million new infections in 2017 with no change to the 
previous year.  More people living with HIV are accessing treatment of which 80% were 
virally suppressed (Avert, 2018).  
In 2014, the World Health Organisation (WHO) set the “90-90-90” target in an attempt to 
incite further action to achieve the interim 2020 goal which is aligned with the ambitious aim 
of ending the AIDS epidemic by 2030 (World Health Organization, 2016). “The targets were 
that: 90% of all people living with HIV will know their HIV status; 90% of all people 
diagnosed with HIV infection will receive sustained antiretroviral therapy; and 90% of all 
people receiving antiretroviral therapy will achieve viral suppression” (World Health 
Organization, 2019).   
The highest concentration of people living with HIV (PLWH) are living in low-and-middle 
income countries (LMIC) with an estimated 53% of the world’s HIV population located in 
Eastern and Southern Africa (Joint United Nations Programme on HIV/ Aids (UNAIDS), 
2018).  South Africa, a Southern African LMIC, has the fourth highest HIV population rate 
with 13.1% of the general population (Statistics South Africa (Stats SA), 2018).  An 
estimated 7.52 million people living with HIV know their status of which 61% are receiving 
ART with only 47% who are virally suppressed; a slow progress towards the achievement of 
the “90-90-90” target (Statistics South Africa (Stats SA), 2018; World Health Organisation, 
2019). 
 
Figure 1. HIV testing and treatment cascade- Eastern & Southern Africa, 2017 
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  (Joint United Nations Programme on HIV/ Aids (UNAIDS), 2018) 
The expansion of access of ART for all people diagnosed with HIV has significantly reduced 
the mortality and morbidity rates of PLWH (World Health Organization, 2016).  According 
to the Joint United Nations Programme on HIV/ AIDS (UNAIDS) 2017 global data, 79% of 
people who knew their HIV status were accessing treatment of which 81% were virally 
suppressed (Avert, 2018).  
 
2.2 Antiretroviral treatment (ART) non-adherence  
Benefits of better physical health and increased life expectancy are largely dependent on 
effective viral suppression.  Currently, there is no official standard measure of adherence to 
predict successful viral suppression; it is generally accepted that a high level of  adherence to 
ART is required (Betancur, Lins, Oliveira, & Brites, 2017; Parienti et al., 2013).  . Author, 
Schaecher (2013) articulated that, “Different classes of antiretroviral therapy (ArT) are 
associated with different thresholds of adherence needed to achieve viral suppression and 
avoid resistance mutations” (p. 231).  The challenge of life-long ART is sustaining a high 
level of adherence (Eshun-Wilson, Rohwer, Hendricks, Oliver, & Garner, 2019)..   
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Previous research has demonstrated that non-adherence to ART is a strong predictor of 
virologic failure (Bottonari, Roberts, Ciesla, & Hewitt, 2005) (Schaecher, 2013; World 
Health Organization, 2016).  In the parent study, a randomised control trial (RCT) which 
investigated the impact of a real-time electronic adherence monitoring device (EAMD) on 
antiretroviral treatment (ART) adherence in ART-naïve individuals conducted by Orrel et al. 
(2015), virologic failure was defined as HIV RNA >40 copies/ml. Virologic failure has life-
threatening consequences such as opportunistic infections, disease progression, drug 
resistance and death, as well as risk of transmission of HIV to sexual partners and unborn 
children (Betancur et al., 2017; Corless et al., 2017; Mutumba et al., 2016). 
2.3 Stressful life events as a barrier to ART adherence 
In South Africa, the majority of PLWH live in disadvantaged communities and frequently 
experience HIV-related challenges such as stigmatisation and discrimination which may be 
compounded by the experience of stressful life events such as interpersonal violence, 
psychological disorders, injuries, serious illness, housing instability, high levels of crime, 
difficulties in relationships, finances and employment; and death (Azia, Mukumbang, & Van 
Wyk, 2016; Kalichman & Kalichman, 2016; O'Donnell et al., 2017).  These challenges are 
typical barriers to ART adherence and are associated with missed pills and follow-up 




The experience of stressful life events by people living with HIV will adversely impact their 
adherence to antiretroviral treatment and therefore affect virologic suppression. 
 
Page 16 of 68 
 
4. PROBLEM STATEMENT 
In South Africa, widespread poor adherence to ART has resulted in a population-wide risk of 
poor viral suppression, development of drug resistance, loss to care and increased mortality.  
Therefore, barriers to adherence in specific communities need to be identified and addressed 
with appropriate strategies.  
 
5. OBJECTIVES 
5. To describe the type and frequency of the life events experienced by PLWH in Gugulethu 
community in Cape Town, over a 48-week period 
6. To investigate the impact of these stressful life events on antiretroviral treatment 
adherence and viral load, measured over a 48-week period. 
 
6. METHODS AND POPULATION 
This secondary analysis will use retrospective data collected in a randomised control trial 
(RCT), previously approved by University of Cape Town Human Research Ethics Committee 
(UCT HREC) with reference 158/ 2012, which investigated the impact of a real-time 
electronic adherence monitoring device (EAMD) on antiretroviral treatment (ART) 
adherence in ART-naïve individuals over a 48- week period from 2012 to 2014.   
230 HIV-infected individuals, both male and female, participated in this study and attended 
the Hannan Crusaid Treatment Centre (HCTC) in Gugulethu, Cape Town.  HCTC is a large 
community-based ART clinic (Orrell et al., 2015).  
The eligibility criteria for the RCT included (1) ART-naive individuals aged ≥15 years old 
who commenced ART at HCTC; (2) who owned mobile phones; and (3) were able to give 
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written consent or assent for participants who were ≤18 years old.  Participation was offered 
to all eligible participants who attended the clinic between July 2012 and March 2013 (Orrell 
et al., 2015).  A simple random sampling strategy was used.  “Participants were randomized 
1:1 to control and intervention arms. Allocation to study arm was concealed in sealed 
individual opaque envelopes, which were numbered from 1 to 230 and opened consecutively 
after a participant met study entry criteria. The random number sequence and envelopes were 
generated off-site. The envelopes were opened by the study nurse, blinded to the allocation, 
onsite. Staff (both study and clinic) and participants were not masked to arm allocation after 
randomization”(Orrell et al., 2015, p. 497).A Recent Life Event (RLE) questionnaire 
(Appendix 1) was administered at week 48 to investigate the contribution of life events to 
poor ART adherence.  The RLE questionnaire included 19 questions on life events in eight 
categories such health, death, relationships, work, crime, birth, housing and other life events 
not mentioned in other categories.  A binary life event variable will be created, defined as any 
life event experienced versus non-experienced.  A continuous variable of frequency (count) 
of life events will also be assessed.  
Other psychosocial covariates measured in the parent study were anxiety and depression 
using a 14-question Hospital Anxiety and Depression Score (HADS) (Appendix 2) and 
alcohol abuse assessed using a four question CAGE score (Appendix 3) (Orrell et al., 2015).   
Depression and anxiety cases were identified using a cut-off score of ≥ 8 for depression and ≥ 
8 for anxiety.  Cases of alcohol abuse were identified using a cut-off score of ≥2.    
Cumulative ART adherence was measured using an electronic adherence monitoring device 
(EAMD, Wisepill®) and “calculated by the number of days the container was opened over 
the number of days in the period in care…” (Orrell et al., 2015, p. 498). 
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Further, to examine the cumulative adherence data and HIV RNA levels: a level of ≥90% of 
the number of pills taken will be considered as adherent and virologic failure will be recorded 
when the HIV RNA levels is ≥ 40 copies/ millilitre.   
 
7. DATA ANALYSIS 
The existing data was cleaned and evaluated using the STATA statistical package version 
13.0.  Further data analysis for this study will be analysed using the same statistical package.  
Descriptive statistics will be used to summarise the baseline demographics, adherence, VL 
measures and psychosocial measures, which will include means, standard deviations, 
medians and interquartile ranges on continuous data and percentages on categorical data as 
well as tabulate the life events data.   
Multivariate logistic regression analysis will be used to explore associations between 
adherence and life events, and between VL and life events.  Life events will be assessed in 
separate models as binary variable and as continuous variable of frequency of events.  Impact 
of potential confounders will be assessed in these models.  Confounders of interest include 
age, gender, depression (binary), anxiety (binary) and alcohol abuse (binary). Collinearity 
between anxiety and depression will also be assessed.  
Of the eight life event categories assessed, the most common life events may be assessed in 
separate logistic regression models.  
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8. LIMITATIONS 
The study is limited in its generalizability.  The study sample was from a disadvantaged 
community with a high rate of unemployment and representativeness for all PLWH cannot be 
assumed.  Selection bias could have occurred due to the number of unemployed participants 
being more available to participate in the study.  Participants enrolled in the index study 
received additional adherence support more than would be expected during routine clinic 
visits.  Weinstein and Li (2016) found that researchers conceptualized stress experienced by 
PLWH in different ways and the current study was limited by the categories of stressful life 
events investigated and cannot be considered exhaustive.  Although, the study will control for 
confounding of other psychosocial variables, which are known to influence medication 
adherence, we cannot exclude the influence of other factors on medication adherence.  
Another limitation of the study is that the Recent Life Event Questionnaire was administered 
at the end of the index study and therefore, data will only be available for the 186 participants 
who completed the study.  However, there is evidence for the importance of considering the 
impact of stressful life events on ART adherence and the need to implement interventions to 
alleviate stress in PLWH. 
 
9. PRESENTATION AND DISSEMINATION OF RESULTS 
A minor dissertation will be submitted in fulfilment of the requirement for the Master of 
Philosophy in Clinical Research Administration degree as per the University of Cape Town 
guidelines. 
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10. FEASIBILITY AND ETHICAL CONSIDERATIONS 
Minimal resources will be required for this study.  Retrospective data for the secondary 
analysis will be provided by the author of the index study, Associate Professor Catherine 
Orrell. 
10.1 Ethical considerations 
The proposed study is a secondary analysis based on retrospective data collected in a clinical 
trial previously approved by the Human Research Ethics Committee of the University of 
Cape Town: HREC Ref no: 158/2012.  University of Cape Town HREC approval for the 
Recent Life Event (RLE) questionnaire is attached (Appendix 4).   
10.2 Informed consent 
In accordance with ethical standards, written informed consent was obtained from each 
participant before enrolment into the index study.  No further informed consent will be 
required for this research and therefore, participants will not be contacted. 
10.3 Risk and benefits to participants 
There are no risks and no direct benefits to the participants.   
10.4 Confidentiality and privacy 
Only de-identified data in the form of code numbers will be shared with no linkage to 
participants’ personal details.  Participant anonymity will be maintained throughout the 
research 
10.5 Data protection and storage 
All data are anonymised and are stored on a password-protected computer.  Access will be 
limited to the researcher.  Only encrypted data will be shared. 
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Optimal antiretroviral treatment (ART) adherence is critical in achieving virologic 
suppression.  ART adherence is used in the assessment of progress towards the 90-90-90 
World Health Organisation global challenge which includes achieving 90% viral suppression 
for all people living with HIV (PLWH) who are on treatment (World Health Organization, 
2016).  Constant monitoring of ART adherence is required to achieve this goal.  The 
expansion of access of ART in developing countries has significantly increased the life 
expectancy of PLWH (Masquelier & Reniers, 2018).  The growing challenges are 
maintaining optimal adherence on lifelong ART, retention in care and achieving viral 
suppression (World Health Organization, 2016).  The Sub-Saharan African region carries the 
highest burden of HIV infection world-wide (53%), with an estimation of 25.7 million 
PLWH (Joint United Nations Programme on HIV/ Aids (UNAIDS), 2018).  The majority of 
PLWH live in resource-poor countries and their lives are complicated by poverty and HIV-
related, as well as life-related stressors.  Identification of barriers to ART adherence, 
including such life stressors, particularly in this context, is important in developing support 
strategies and differentiated care models (Azia, Mukumbang, & Van Wyk, 2016; Nachega, 
Sam-Agudu, Mofenson, Schechter, & Mellors, 2018).   
 
This literature review aims to examine all published studies which report on stressful life 
events in PLWH, with ART adherence or a viral load as an outcome.  This review will 
include published literature from 2008 to 2019 and will include both resource-poor and 
resource-rich contexts with no differentiation in study design. 
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2. OBJECTIVES OF THIS LITERATURE REVIEW ARE TO REPORT 
 
• Stressful life events (SLEs) in PLWH 
• Covariates associated with poor adherence 
• Measures of ART adherence and virologic outcomes 
 
3. LITERATURE SEARCH STRATEGY 
 
A search for published studies was conducted using the following databases: Pubmed, 
MEDLINE, Google Scholar, CINAHL, PsycINFO and SCOPUS.  A combination of key 
words and Medical Sub-headings such as “HIV OR human immunodeficiency virus” AND 
“stressful life events OR life events OR life change events” AND “antiretroviral therapy” 
AND “adherence OR compliance” were used to obtain relevant literature.  Limiters applied in 
this search were full text and peer-reviewed articles in the English language with age 
restricted to adults of 18 years and older.  To be included, the literature had to identify 
“stressful life events OR life events” as exposure variable and “ART adherence or viral load” 
as an outcome variable. 
 
4. RESULTS OF LITERATURE SEARCH 
 
The search generated 24 articles of which only 12 met the inclusion criteria. Among these 
studies, 9 studies were conducted in a high-income country (HIC), one in a lower-middle 
income country (LMIC) and two studies included sites from both HIC and LMIC.  HIC and 
LMIC are classified by the World bank according to the country’s income level (World 
Bank).  The 9 studies from HICs included: 7 from the US and 1 study from Australia and 1 
Page 25 of 68 
 
study which included 4 HIC sites (Table 1).  The only LMIC study was from South Africa.   
Two studies conducted by Corless et al. (2013 & 2017) included sites from both, HIC 
(Canada, US, Puerto Rico) and LMIC (Namibia, Thailand, China).  One systematic review 
conducted by Weinstein et al. (2016) was included.  The systematic review examined the link 
between stress and treatment adherence, immunological outcomes, virologic outcomes and 
disease progression; in the selected literature.   Studies mentioned in this literature review 
were not mentioned in the systematic review.  Nine studies reported on adherence as a 
primary outcome, one study reported a virologic outcome and two reported both an adherence 
and virologic outcome.   
 
4.1 Stressful life events (SLEs) in people living with HIV (PLWH) 
 
SLEs can cause major disruption in the lives of PLWH resulting in negative adherence 
behaviour and poor health outcomes (O'Donnell et al., 2017).  PLWH and living in poverty 
have added challenges contributing to increased non-adherence.  SLEs have been described 
in various ways such as HIV-related stressors, non-HIV related stressors, life experiences, 
psychological stressors or biological markers linked to stress (Weinstein & Li, 2016).  The 
impact of SLEs on ART adherence may depend on the number of events experienced and/ or 
the type of SLEs.  Studies varied in stress measures used, prevalence rates and common 
stressful life events. 
 
4.1.1   Stressful life event measures 
 
Various validated self-reporting stress measures were used across the 12 studies.  Weinstein 
et al. (2016) reported findings of 22 different measures that were used across 23 studies.  The 
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57-item Life Experiences Survey (LES) developed by Saranson et al. (1978) was modified, 
validated and commonly used in four studies (Leserman, Ironson, O'Cleirigh, Fordiani, & 
Balbin, 2008; Mugavero et al., 2009; O'Donnell et al., 2017; Reif et al., 2011). The LES 
captured moderate and severe stressful life experiences such as relationship difficulties, death 
or serious illness, financial problems, employment difficulties, legal problems, sexual or 
physical abuse and housing difficulties.  Other studies used scales previously developed and 
validated which were typically used in studies of mental health in PLWH (Brinkley-
Rubinstein, Chadwick, & Graci, 2013; Kalichman & Grebler, 2010; Kalichman & 
Kalichman, 2016; Siefried et al., 2017).  Corless et al. (2013 & 2017) developed and used a 
20-item Stressful Life Event Questionnaire modified from the List of Threatening 
Experiences Questionnaire [LTE-Q; (Brugha & Cragg, 1990)] which measured similar 
experiences of SLEs such as death or serious illness, injury, unemployment and stigma.  
Bottonari et al. (2010), differentiated between chronic, acute and perceived stress using the 
Chronic Strain Interview [CSI; (Hammen et al., 1987)], the Life events and difficulties 
schedule [LEDS; (Brown, 1989)] and the Perceived stress scale-4 item version [PSS; (Cohen, 
1988)], respectively. 
 
4.1.2   Prevalence of SLEs 
 
Nine of the 12 studies reported the high prevalence of SLEs and their association with a 
negative adherence outcome.  In two studies, based on data from the Coping with HIV/ AIDS 
in the Southeast (CHASE) study, Mugavero et al. (2009) reported medians of nine incident 
stressful events including three incident severely stressful events over a two-year period, and 
Reif et al. (2011) reported medians of three stressful experiences and one severely stressful 
experience over a nine-month period.  Two studies, conducted by Kalichman et al. (2010 & 
2016), found a higher number of SLEs experienced by the non-adherent group compared to 
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the adherent group, i.e means of 4.3-4.7 vs 3.5.   Both, Corless et al. (2013) and Bottonari et 
al. (2010) found a mean of 5.6 SLEs experienced by the total study sample over one month.  
Other studies reported a mean of 2-3 SLEs measured over different periods (Leserman et al., 
2008; O'Donnell et al., 2017; Siefried et al., 2017).  
 
4.1.3   Common Stressful life events 
 
Findings of the most common stressful life events within the study sample differed among the 
studies.  Ongoing financial stressors, serious illness or death of a partner, friend or family 
member and unemployment ranked the highest across most studies (Table 2).  Some studies 
mentioned relationship difficulties, food insecurity, housing instability, lack of transport, 
safety issues and legal problems as high-ranking stressors (Bottonari, Safren, McQuaid, 
Hsiao, & Roberts, 2010; Kalichman & Grebler, 2010; Kalichman & Kalichman, 2016; 
Leserman et al., 2008; Mugavero et al., 2009; O'Donnell et al., 2017; Reif et al., 2011).   
 
Eleven of the studies described the SLE experiences of PLWH in HIC and may not be 
generalizable to PLWH in resource-limited settings, however it gives an indication that 
populations living in resource-limited settings may be at higher risk of increased SLEs and 
chronic stress which may impact their ability to maintain optimal adherence. 
 
4.2 Covariates associated with poor adherence 
 
All studies included numerous psychosocial measurements given the significance of these 
variables in the prediction of medication adherence.  Confounding factors examined in the 
literature were: depression, alcohol and drug use, anxiety, HIV care self-efficacy, coping 
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styles, HIV status disclosure, stigma, quality of life of PLWH, self-esteem, sense of 
coherence, self-compassion, poverty experiences, life chaos and adult literacy. 
 
Depression was reported in eleven studies using various validated scales. Commonly used 
scales were: the Center for Epidemiological Studies-Depression Scale [CES-D; (Radloff, 
1977)], the Brief Symptoms Inventory measured depression and anxiety [BSI; (Derogatis & 
Melisaratos, 1983)], the Beck Depression Inventory [BDI; (Beck, Ward, Mendelson, Mock, 
& Erbaugh, 1961)], the Hamilton Depression Rating Scale [HDRS; (Hamilton, 1960)] and 
the Montgomery-Asberg Depression Rating Scale [MADRAS; (Montgomery & Asberg, 
1979)].  Weinstein et al. (2016), reported the Hospital Anxiety and Depression Scale 
[(HADS; (Zigmond & Snaith, 1983)] that was used in two studies.  Brinkley-Rubinstein et al. 
(2013) reported mental health notations from medical notes.  
 
Alcohol and drug use was assessed in seven studies: Siefried and colleagues (2017) used the 
‘Cut-Annoyed-Guilty-Eye’ questionnaire [CAGE; (Ewing, 1984)]; Kalichman et al. (2010 & 
2016) used the Alcohol Use Disorders Identification Test [AUDIT; (Maisto, Conigliaro, 
McNeil, Kraemer, & Kelley, 2000)] in two studies; both, Reif et al. (2017) and Mugavero et 
al. (2009) used the Addiction Severity Index [ASI;(Cacciola, Alterman, McLellan, Lin, & 
Lynch, 2007)]; and O’Donnell et al. (2017) reported using the Mini International 
Neuropsychiatric Interview [MINI; (Lecrubier et al., 1997)] to assess alcohol and drug use.  
Health behaviours such as alcohol use and cigarette smoking were examined by Leserman et 
al. (2008) in less detail.   
 
Based on evidence indicating the negative influence of SLEs on the overall quality of life of 
PLWH; Corless et al. (2013 & 2017) uniquely examined the sense of coherence, self-
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compassion, adherence self-efficacy and the engagement with healthcare providers as 
mediators of SLEs on ARV adherence and found these combined variables were significant 
predictors of adherence.  Adherence self-efficacy which “measures the confidence of the 
respondent in completing treatment-associated behaviours and incorporating those behaviors 
into daily life as appropriate”; was found to be the strongest predictor of ART adherence in 
this study (Corless et al., 2017, p. 229).     
  
Despite major advances in the acceptability of ART and the escalation to ART access, PLWH 
continue to face challenges of disclosure, stigma and discrimination which impede the uptake 
of treatment as well as maintaining adequate ART adherence.  Some HIV populations 
experience increased vulnerability, particularly girls and women in Sub-Saharan Africa, who 
are exposed to gender-inequality and gender-based and sexual violence (World Health 
Organization, 2016).   The focus is therefore for healthcare systems to create an enabling 
environment by developing policies and practices that would address stigma and 
discrimination and encourage disclosure among PLWH.  Six studies reported stigma and 
discrimination as additive stressors to adherence using self-reporting questionnaires with 
findings consistent with previous research which found stigma and discrimination as strong 
predictors of non-adherence (Corless et al., 2013; Corless et al., 2017; Kalichman & Grebler, 
2010; Kalichman & Kalichman, 2016; O'Donnell et al., 2017; Siefried et al., 2017).  Siefried 
et al. (2017), found more than 40% of the cohort reported to be shamed, blamed and/ or 
rejected or excluded after disclosing their HIV status. 
 
Coping styles were examined in four studies using the Brief Cope instrument (Carver, 1997) 
to determine the mediating effect of maladaptive coping on the relationship between SLEs 
and adherence (Bottonari et al., 2010; Mugavero et al., 2009; O'Donnell et al., 2017; Reif et 
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al., 2011).  Mugavero et al. (2009) and Reif et al. (2011) used similar definitions of coping 
styles; forming two scales of adaptive (positive reframing, using emotional support, 
acceptance, religion, active) and maladaptive (denial, self-blame, and behavioural 
disengagement) coping styles.  Bottonari et al. (2010) broadened the dimensions of coping by 
using two factors which consisted of: “Active coping” (emotional support, instrumental 
support, planning, positive reframing, humor, acceptance, and religion) and “Avoidant 
coping” (denial, substance use, behavioral disengagement, venting, and self-blame).  
Although Reif et al. (2011) found maladaptive coping to be associated with stressful 
experiences, other studies reported SLEs predicted non-adherence after adjusting for 
covariates such as coping styles (Bottonari et al., 2010; Mugavero et al., 2009; O'Donnell et 
al., 2017).  
 
Kalichman et al. (2010 & 2016) examined the link between poverty markers (food and 
housing insecurity) and ART adherence with stressors and life-chaos as mediators; the studies 
also reported stressors (social, health-related and HIV-related) and life chaos as predictors of 
non-adherence.  Further findings reported in these studies were: food insufficiency and 
hunger as a strong predictor of non-adherence in a low-literacy study population and the 
addition of stressors and chaos as mediators resulted in a non-significant association between 
poverty markers and ART adherence.  These studies reported the need to address food 
insufficiency together with interventions to manage stress in PLWH, particularly in 
disadvantaged populations, to improve ART adherence. 
 
4.3 Measure of ART adherence  
 
Medication adherence is defined as the extent to which a person correctly takes the 
medication as prescribed by the healthcare provider (Nachega, Mills, & Schechter, 2010).  
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Previous literature suggested various adherence levels of 70% to ≥95% to achieve virologic 
suppression (Nachega et al., 2010).  Adherence is defined in various ways in the selected 
literature:  four studies, using self-reporting measures, defined non-adherence as missed 
doses over the past 7 days, past 2 weeks, past 30 days and the previous weekend (Bottonari et 
al., 2010; Leserman et al., 2008; Mugavero et al., 2009; Siefried et al., 2017); and four studies 
defined adherence as more than 85 -90% of pills taken over a specified period (Brinkley-
Rubinstein et al., 2013; Kalichman & Grebler, 2010; Kalichman & Kalichman, 2016; 
O'Donnell et al., 2017).  Adherence was not defined in three of the studies (Corless et al., 
2013; Corless et al., 2017; Weinstein & Li, 2016). 
 
Multiple measures to estimate adherence are reported in published literature.  Methods used 
can be direct such as therapeutic drug monitoring (TDM) which measures the level of the last 
dose of the drug taken or indirect methods such as self-reporting (SR), clinic-based pill 
counts (CPC), pharmacy-refills (PR) or electronic adherence monitoring (EAM) (Glass & 
Cavassini, 2014; Orrell et al., 2017).  Although adherence thresholds to predict treatment 
success remains undefined; a high level of adherence is reportedly accepted as determinant of 
optimal viral and immunological outcomes.  SR, CPC and PR are commonly used in clinical 
care in resource-limited settings.  Although these methods are often inaccurate and 
overestimate adherence, they are the most accessible and feasible measures of adherence  to 
collect (Orrell et al., 2017).  There is no single optimal measure of adherence; therefore, 
using a multi-method approach is more likely to provide an accurate measure of adherence 
behaviour (Glass & Cavassini, 2014).  In this review, seven studies reported a self-reporting 
method, three studies used an unannounced telephonic pill-count method and one reported a 
clinician pill count.   
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SR measures are low-cost and convenient; but are largely subjected to recall bias and 
intentional deception due to social desirability bias (Glass & Cavassini, 2014).  Using 
validated SR instruments allows for assessment of four dimensions of adherence behaviour: 
assessment of number of pills taken, timing compliance, missed doses and food intake (Glass 
& Cavassini, 2014).  Validated SR instruments were used in six studies: two studies used a 
30-day Visual Analog Scale for medication adherence [one-item scale adapted from MASRI 
scale;(Walsh, Mandalia, & Gazzard, 2002)]; three studies used a modified version of the 
Adult AIDS Clinical Trial Group instrument [AACTG: (Chesney et al., 2000)] and one study 
used a Simplified Medication Adherence Questionnaire [SMAQ:(Knobel et al., 2002)] 
(Bottonari et al., 2010; Corless et al., 2013; Corless et al., 2017; Leserman et al., 2008; 
Mugavero et al., 2009; Siefried et al., 2017).  Using the 30-day Visual Analog Scale, 
participants had to indicate on a scale of 0% to 100% the amount of time they have taken 
their medication as prescribed.  The questionnaires interrogated medication adherence using 
responses to number of pills taken and missed doses over a specified period.  O’Donnell and 
colleagues (2017) reported a self-reporting method using a telephonic structured interview to 
record responses to questions on pills taken and missed doses over the previous month.  
Periods of measurement or recall varied from the past 7 days up to the past 30 days.  Short 
recall periods of 3 to 7 days have been suggested in several studies to maximise recall and 
minimise bias (Lu et al., 2008).  Recent evidence suggests that longer recall periods of 30 
days and including the previous weekend may be more optimal in measuring missed doses 
and in determining patterns of adherence behaviour (Lu et al., 2008; Walsh et al., 2002).   
 
Kalichman et al. (2010 & 2016) and O’Donnell et al. (2017) reported an unannounced 
telephonic pill count-method to assess medication adherence.  In previous research, 
Kalichman and colleagues (2007) found this method in assessing medication adherence to be 
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reliable and valid when followed-up with unannounced home visits to repeat pill counts.  
Unannounced telephonic pill counts were performed at various intervals in the three studies: 
once a month, at 12-16 day- or at 21-35 day-intervals. 
 
Brinkley-Rubinstein et al. (2013) reported adherence based on clinician pill counts notated in 
medical charts.  Adherence lapses were noted when adherence was reduced to less than 90%.   
The systematic review reported the measurement of ARV adherence in eleven studies; 
methods were unspecified (Weinstein & Li, 2016).  Three studies reported >1 adherence 
measure: Siefried et al. (2017) and Kalichman et al. (2010) reported pharmacy refills as 
additional adherence measure and O’ Donnell et al. (2017) used a self-reporting measure as 
well as unannounced telephonic pill-count. 
 
Nine of the 11 studies which assessed adherence reported proportions of adherent participants 
ranging from 33-96%.  Estimates from two studies using unannounced telephonic pill-counts 
(calls at 12-16 day- or at 21-35 day-intervals) with a cut-off of 85% reported proportions of 
adherence of 33% and 47%, respectively (Kalichman & Grebler, 2010; Kalichman & 
Kalichman, 2016); compared to another study using the same adherence measure with 
monthly calls and a cut-off of 95% which reported a median adherence of 96% (O'Donnell et 
al., 2017). 
 
4.4 Virologic outcome 
 
HIV RNA results were selected from a medical record abstraction in five studies, one study 
measured viral load at baseline and one systematic review reported virologic outcomes in 12 
studies (Bottonari et al., 2010; Kalichman & Grebler, 2010; Kalichman & Kalichman, 2016; 
Leserman et al., 2008; Mugavero et al., 2009; Reif et al., 2011; Weinstein & Li, 2016).  
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Virologic failure (VF) was defined in three studies: Bottonari et al. (2010) defined VF as HIV 
RNA levels as >50 copies/ ml and both, Mugavero et al. (2009) and Reif et al. (2011) defined 
VF as HIV RNA levels >400 copies/ ml.  The proportion of virally suppressed participants 
varied across four studies ranging from 46 – 71% and proportions were not reported in three 
studies (Kalichman et al., 2010 & 2016; Reif et al. 2011; Bottonari et al., 2010). Kalichman et 
al. (2010) reported viral suppression of 72% in a non-adherent group at a threshold of 85% 
adherence with an overall of 71% of the cohort that were virally suppressed.  Leserman et al. 
(2008) measured HIV RNA at baseline with no report of the results of this measurement.  
Poor adherence was not reported to be associated with poor virologic outcomes in any of the 
studies. 
 
 4.5 Stressful life events (SLEs) as predictor of adherence and virologic outcome 
 
SLEs were reported to be consistently associated with non-adherence or missed pills in the 
eleven studies which reported an estimation of adherence.  A high number of SLEs were 
associated with non-adherence and the addition of one SLE predicted the deterioration of 
ART adherence.   
 
Weinstein et al. (2016) reported 12 studies in the systemic review which measured virologic 
outcomes, four of the studies found SLEs to be associated with VF and eight studies found no 
significant relationship between SLEs and VF. Reif et al. (2011) also found no association 
between SLEs and VF; in contrast, Mugavero et al. (2009) reported a significant association 
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5. STUDY RATIONALE 
 
There is a paucity of literature on stressful life events in PLWH and its impact on ART 
adherence and virologic outcomes in LMIC, particularly in South African context.  Although 
some of these stressful experiences in PLWH have been reported in a recent South African 
study with encouraging findings, the number of stressful life events assessed were limited.  
While published studies in developed countries, indicated significant associations between 
SLEs and adherence and/ or viral load, comparability was limited by the different methods 
used to assess SLEs and adherence as well as the different definitions and thresholds of 
adherence and virologic outcomes.  To increase understanding of the impact on SLEs on 
adherence in a LMIC, an assessment of a comprehensive range of potential stressful life 
experiences using multiple measures of adherence validated with viral load, are needed.  This 
study aims to provide information on SLEs in PLWH and adherence and virologic outcomes, 
using an electronic monitoring adherence measure and viral loads. 
 
 
Page 36 of 68 
 




Location Time Study design Study population 
Siefried et al. 2017 Australia Sep 2013-Nov 2015 Cross-sectional study of a baseline 
sample 
522 -virally suppressed at baseline 
Males=494 (94.6%) 
Mean age 50.8 years 
O’Donnell et al. 2017 USA (North Carolina) Jul 2011- Sep 2013 Secondary analysis - data from a RCT 
12 month follow-up 
289-clinically depressed 
participants -Male (71%)  
Median age of 45 years.  
Corless et al. 2017 Canada, Namibia, Thailand, United States, 
Commonwealth of Puerto Rico 
Not reported Cross-sectional study  1811 -Males (71%) 
Weinstein and Li 2016 USA, The Gambia, Spain, Hong Kong  Published articles 
between 1995 and 2012. 
Systematic review 23 articles 
Kalichman & 
Kalichman 
2016 USA (Georgia) Dec 2013- Mar 2014 Observational study – 6-week 
prospective period 
92 -Male (83.6%)  
Brinkley-
Rubinstein et al. 
2013 South Africa (Western Cape) Not reported Systematic, retroactive review of 
medical charts 
171 - Males (28%) 
Mean age of 39 years 
Corless et al. 2013 USA (14 sites), Canada (1 site), 
China (1 site), Namibia (1 site), 
Puerto Rico (1 site), Thailand (1 site) 
Sep 2009 - Jan 2011  Multi-site cross-sectional investigation  2082 -Males (68.3%; n=1404)  
Mean age of 44.9 years  
Reif et al. 2011 USA (South-eastern states) Dec 2001- Apr 2002 Secondary analysis  611 (589 surveyed)- Males (69%) 
Mean age of 40.1 years 
Kalichman and 
Grebler 
2010 USA (Georgia) Oct 2008-Aug 2009 Prospective study - 3 months duration 188 poor literacy -Males (69.1%) 
Mean age of 46.7 years 
Bottonari et al. 2010 USA  Not reported Prospective study - baseline & 3-month 
follow-up 
87 - Males (54%) 
Mean age 46 years 
Mugavero et al. 2009 USA (South-eastern states) 2001-2002 Prospective study- follow-up over 27 
months in an 8-site, 5-state study 
474 at baseline - Males 71% 
289 at 27-month follow-up 
Median age of 40 years 
Leserman et al. 2008 USA (South Florida) 2004-2007 Cross-sectional study 105 - Male= 61% 
Mean age 44 
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Table II. Stressors, Covariates, Adherence and Virologic outcomes 
Authors Most common stressors Number of events  Covariates 
Adherence 
definition 
*Method Adherence outcome Virologic outcomes 




Living in subsidized 
housing 
Experienced >2 major stress 
events in previous 12 months 
(25.5%) 
Depression 
Alcohol and illicit drug use 
HIV disclosure 
Stigma 
Missed one dose per 
month  
SR, PR 78 participants (14.9%) reported 
missing doses. 
Socioeconomic, cultural, social, 
relationship, and patient 
engagement factors associated to 
suboptimal adherence 
Not reported 





Death/serious illness of 
family member/friend 
Median of 2 events per 
month 
Depression 




HIV status disclosure 
Employment status 
Drug and/or alcohol abuse. 
Adherence >95% UTPC, 
SR 
Median monthly adherence 96%  
SR at baseline -median of 98%  
Pill count-measured median 96%  
 
Greater number of past-month 
SLEs was associated with poorer 
past-month ARV adherence 
Not reported 
Corless et al. 
(2017) 
Not specified Not specified Engagement with HCP, 
Self-esteem, Perceived 
stigma, Sense of 




None (0%), Low 
(1–60%), Moderate 
(61–94%), and High 
(95–100%)  
SR High (95–100%) -52.3%   
Medium (61–94%) - 33.3%  
Low (1–60%) - 8.3% 
None - 6% 
Stressful life events were 





Not specified Not specified Anxiety  
Depression 
Not reported  Not 
reported 
Adherence was measured in 11 
studies. 
Higher stress was found to be 
related to poorer treatment 
adherence in 5 studies (22%) and 
not significant in 6 studies. 
Viral load measured in 12 
studies (52%)  
Stress was related to higher 







Lack of transportation 
Housing instability  
HIV related stressors: 
Adherence <85%= mean 4.7  
Adherence >85%)= mean 3.5 
 
Poverty markers: 
Adherence <85% =mean 4.7 







Adherence >85% UTPC Non-adherence 54% (n=50) 
Life chaos with HIV-related 
stressors, is associated with both 
non-adherence and poverty.  
29% were not HIV virally 
suppressed 
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Brinkley-
Rubinstein et al. 
(2013) 
Death or illness of friend or 
family member  
Not specified Mental health notations Adherence >90% HP-PC Non-adherence 47% (n=81), 
Serious life event was 
significantly associated with anti-
retroviral adherence lapse and 
mental health issues.  
Not reported 
Corless et al. 
(2013) 
Unemployed (75%) SLEs mean 5.69 (SD=4.88) 
and 89% of the sample had 
at least one SLE.  
Sense of Coherence  
Self Compassion  
Engagement with 
Healthcare Provider  
Stigma 
Not reported SR Canadian: 3 days (M=86.49) or 
30 days (M=84.12); 
Namibian:3 days (M=96.21) or 
30 days (M=95.81). 
 
SLE, SCS, SOC, and eHCP were 
significant predictors of 
adherence  
Not reported 
Reif et al. 
(2011) 
Financial stress 
Major illness or injury 





experiences - median 3.5 
experiences and 10% of 
study participants reported 
traumatic stress in any given 
nine-month period 
Depression 




Not reported Not 
reported 
Not reported VL<400cps/ml = 237 
(46.1%) 
 
Viral load was not 







Relationship difficulties  
Total stressors:  
Adherence >85% = 3.5 





Alcohol and substance use 
Adherence >85% UTPC, 
PR 
Non-adherence 67% (n=127) 
 
Social and health-related 
stressors were associated with 
ART adherence.  
Undetectable VL: 
<85% = 92/ 127 (72.4%) 
>85% = 42/ 61 (68.9%) 
Total = 134/ 188 (71.3%) 





Serious illness among 
family members 
Measured at baseline (T1) 




T2 LEDS = 5.6 
T2 CSI = 13.6 
T2 PSS = 6.7 
Adult literacy 
Brief Cope inventory 
Depression 
Major Depressive Episode 
(MDE) 
Number of missed 
doses in the past 30 
days 
SR 47% (n = 41) reported 100% 
adherence at either 3- or 30- day 
assessment and 33% (n = 29) 
reported perfect adherence for 
both periods. 
 
Acute life events and chronic 
stress prospectively predicted 
decreases in treatment adherence  
Virologic failure defined as 
HIV VL > 50cps/ ml 
Undetectable viral loads = 
62% 
Mugavero et al. 
(2009) 
Financial difficulties 
Serious injury or illness 
Death of a family member 




Median of 9 incident 
stressful events, including 3 
incident severely stressful 
events 
Depression 
Alcohol and drug use 
Coping styles 
 Missed doses 
during the past 7 
days;  
SR Relationship, safety-related, and 
life transition stresses were 
associated with decreased 
adherence  
 
Non-adherence (n=60) 21% 
Virologic failure defined as 
HIV VL >400cps/ ml 
 
Relationship stresses and 
injuries, accidents, and non-
HIV related illnesses 
predicted virologic failure 
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Relationship difficulties - 
arguments, separation, 
estrangement 
Serious illness or injury 
Unemployment  
Death of close friend or 
family member 
Median 3 events Depression 
Alcohol and substance use 
Missed doses in the 
past 2 weeks or 
previous weekend 
SR 44.8% had missed a medication 
dose in the past 2 weeks, and 
22.1% had missed their 
medication during the previous 
weekend.  
Stressful life events were 
consistently associated with 
missing HIV medication 
Blood draw at baseline-
CD4 and HIV RNA viral 
load. 
*Methods: Unannounced Telephonic Pill-counts (UTPC), Self-reporting (SR), Health Provider Pill-count (HP-PC), Pharmacy Refills (PR) 
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People living with HIV (PLWH) experience HIV-related challenges which may be compounded by the 
experience of stressful life events (SLE), impacting their ART adherence and affect virologic outcome.   
A secondary data analysis was conducted to examine the impact of SLE on ART adherence and viral 
load among ARV-naïve individuals. A recent life event questionnaire was administered including life 
events in eight categories: health, death, relationships, work, crime, birth, housing and other. 
200 participants completed the questionnaire. 67,5% were female, with a median age of 32.7 (IQR 
27.4-41.1) years. A total number of 353 life events were recorded, a median of 1.0 (IQR 0-3) SLEs per 
person.  A significant association was found between the total number of events experienced and 
virologic failure (OR 1.3, CI 1.06 -1.60, p=0.011). Age was protective (aOR 0.92, CI 0.85-0.99, 
p=0.042).  Poor birth outcomes (a personal or household experience of a miscarriage, termination of 
pregnancy or still birth) were strongly associated with poor adherence (aOR 6.45, CI 1.25-33.29, 
p=0.026) and virologic failure (aOR 8.88, CI 1.56-50.58, p=0.014).   
People with multiple SLEs, including poor birth outcomes, and younger individuals, are at higher risk 
of virologic failure and/or poor adherence. These associations highlight the need for differentiated 
care models; providing focussed support for younger PLWH, pregnant and postpartum women. 
Keywords: Human Immunodeficiency Virus (HIV), Stressful life events (SLE), antiretroviral therapy 
adherence, virologic failure 





The 2017 HIV statistics revealed that globally, an estimated 36.9 million people were living with HIV, 
including an estimated 1.8 million new infections; with no reduction in these new infections from 
the previous year.  More people living with HIV are accessing treatment and on average 80% of them 
were virally suppressed (1).  
In 2014, the World Health Organisation (WHO) set the “90-90-90” target in an attempt to incite 
further action to achieve the interim 2020 goal which is aligned with the ambitious aim of ending the 
AIDS epidemic by 2030 (2). “The targets were that: 90% of all people living with HIV will know their 
HIV status; 90% of all people diagnosed with HIV infection will receive sustained antiretroviral 
therapy; and 90% of all people receiving antiretroviral therapy will achieve viral suppression” (3).   
The highest concentration of people living with HIV (PLWH) is in low-and-middle income countries 
(LMIC) with an estimated 53% of the world’s HIV-positive population located in Eastern and 
Southern Africa (4).  South Africa, a Southern African LMIC, reported 13.1% of the general 
population to be HIV-infected (5).  An estimated 7.52 million people living with HIV in South Africa 
know their status,  61% of these people are receiving ART, but only 47% are virally suppressed: slow 
progress towards the achievement of the “90-90-90” target (5, 6). 
The expansion of access of ART for all people diagnosed with HIV has significantly reduced the 
mortality and morbidity rates of PLWH (2).  According to the Joint United Nations Programme on 
HIV/ AIDS (UNAIDS) 2017 global data, 79% of people who knew their HIV status were accessing 
treatment of which approximately 80% were virally suppressed globally (1).  
Benefits of better physical health and increased life expectancy are largely dependent on effective 
viral suppression. Suppression depends on people remaining in care and being adherent to their 
ART.  Currently, there is no official standard measure of adherence to predict successful viral 
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suppression; it is generally accepted that a high level of  adherence to ART is required (7, 8).  Author, 
Schaecher (2013) articulated that, “Different classes of antiretroviral therapy (ART) are associated 
with different thresholds of adherence needed to achieve viral suppression and avoid resistance 
mutations” (p. 231).  The challenge of life-long ART is sustaining this high level of adherence (9).  
The converse is also true: previous research has demonstrated that non-adherence to ART is a strong 
predictor of virologic failure (10) (2, 11).  Virologic failure has life-threatening consequences such as 
opportunistic infections, disease progression, drug resistance and death, as well as risk of 
transmission of HIV to sexual partners and unborn children (7, 12, 13). 
In South Africa, the majority of PLWH live in disadvantaged communities and frequently experience 
HIV-and ART-related related challenges such as stigmatisation and discrimination which may be 
compounded by the experience of stressful life events such as interpersonal violence, psychological 
disorders, injuries, serious illness, housing instability, high levels of crime, difficulties in relationships, 
finances and employment; and death (14-16).  These challenges are typical barriers to ART 
adherence and are associated with missed pills and follow-up appointments (14, 16, 17).   
To improve our understanding of adherence behaviours, we examined the association between 
stressful life events and ART adherence in an ARV-naïve group over a 48-week period using 
electronic adherence monitoring as an objective adherence measure.  In this secondary analysis, we 
hypothesized that the experience of stressful life events by PLWH will adversely impact their 
adherence to antiretroviral treatment and therefore affect virologic suppression.   Covariates 
included in the analyses: age, gender, depression, anxiety and alcohol use are based on previous 
research which examined psychosocial  and socio-demographic factors and found these factors to be  
significant predictors of nonadherence and virologic failure, particularly amongst PLWH in LMICs (7, 
18-20).  A recent Nigerian study reported a strong association between depression and negative life 
events; with women experiencing more negative life events than men (21).   
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METHODS  
Study design, setting and population 
 
A secondary analysis was conducted using retrospective data collected from a randomised control 
trial (RCT), previously approved by University of Cape Town Human Research Ethics Committee (UCT 
HREC reference 158/2012), which investigated the impact of a real-time electronic adherence 
monitoring device (EAMD) - Wisepill® -on antiretroviral treatment (ART) adherence in ART-naïve 
individuals over a 48- week period from 2012 to 2014 (22).   
 
Parent study  
230 HIV-infected individuals, both male and female, participated in the parent study. They attended 
the Hannan Crusaid Treatment Centre (HCTC), a large community-based ART clinic in Gugulethu, 
Cape Town – a peri-urban area with high levels of poverty and unemployment (22).  
The eligibility criteria for the RCT included (1) ART-naive individuals aged ≥15 years old who 
commenced ART at HCTC; (2) who owned mobile phones; and (3) were able to give written consent 
or assent for participants who were ≤18 years old.  Participation was offered to all eligible 
participants who attended the clinic between July 2012 and March 2013 (22).  Convenience sampling 
was used and eligible “participants were randomised 1:1 to control and intervention arms. (22).   
Secondary analysis 
200 participants completed the RLE questionnaire shortly after the end of the study (week 48) and 
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Data sources and measures  
 
Several data sources obtained from the parent study were used for this analysis. The methods of the 
parent study have been described elsewhere (22).  Baseline (week 0) demographic details taken 
from the parent study included age, gender, weight, height, CD4 count and viral load. Week 48 viral 
load was also collected.  
Psychosocial covariates measured in the parent study included the 14-question Hospital Anxiety and 
Depression Score (HADS); and the four question CAGE score to identify alcohol issues (22).  Both the 
HADS and CAGE questionnaires were completed at the Week 48 visit.  Depression and anxiety were 
considered present in those with a HADS score of ≥ 8 for depression and/or ≥ 8 for anxiety.  A CAGE 
score ≥2 indicated significant alcohol use.    
Stressful life events were assessed using a Recent Life Event (RLE) questionnaire administered 
shortly after the week 48 visit to investigate the life events perceived to impact poor ART adherence.  
The RLE questionnaire included 19 questions on life events in eight categories such health, death, 
relationships, work, crime, birth, housing and other life events not mentioned in other categories. 
This was analysed as a continuous variable of frequency (count) of life events.  
Cumulative ART adherence was measured using an electronic adherence monitoring device (EAMD, 
Wisepill®) and “calculated by the number of days the container was opened over the number of days 
in the period in care…” (22). For categorical analysis, taking ≥80% of the expected number of pills 
was considered to be adherent; and people were considered to have virologic failure with a week 48 









Data were cleaned and analysed using the STATA statistical package version 13.0 (STATA 
Corporation, College Station, TX).   
Descriptive statistics were used to summarise the baseline demographics, adherence, VL measures 
and psychosocial measures: mean with standard deviations or median with interquartile ranges 
(IQR) for continuous data; and percentages for categorical data and to tabulate the frequency of life 
events data.  The Chi-square test of independence was used to compare proportions. 
Multivariate logistic regression analysis with preselected covariates were used to explore 
associations between life events and ART adherence, and between life events and virologic failure.   
Individual SLEs were initially assessed in separate bivariate models to determine associations with 
ART adherence and VL; and SLEs with significant associations were included in the multivariate 
logistic regression models.    Confounders of interest included age, gender, depression, anxiety and 
alcohol abuse, commonly found to influence adherence and VL, were assessed in these models.  
 
Ethical approval 
Ethics approval was obtained from the University of Cape Town Faculty of Health Science Research 
Ethics Committee, HREC reference 633/ 2019.  All participants provided written informed consent in 




200 participants reached week 48 in the parent study (30 were lost to follow-up) and completed the 
Recent Life Event (RLE) questionnaire at the end of study; they comprised the cohort for this sub-
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study with a median age of 32.7 years (IQR 27.4-41.7) and a predominance of females (67.5%).  Most 
participants were in age groups 25-34 years (46.5%) and 35-44 years (28.5%).  
Table I. Baseline demographics and psychosocial characteristics of parent and sub-
study cohorts 
 
At week 48, the median adherence in the sub-study cohort (n=200), was 82% (IQR 53-94%), 
indicating the cohort took medication 82% of the time according to the Wisepill® count.  At week 48, 
108 (54%) participants achieved an adherence level of ≥80% and 92 (46%) were <80%. adherent.  
162 (89%) achieved viral suppression (HIV RNA ≤50 copies per millilitre) and 20 (11%) had virologic 
failure.  Eighteen participants missed HIV-RNA testing at week 48.  Compared to participants who 
had a HIV-RNA result at week 48, these participants were younger (28.6 years, IQR 26.8-34.1), 
 Parent cohort Sub-study cohort 
n = 200 
With VL at week 
48 
Without VL at 
week 48 
N 230 200 182 18 
Female sex: n (%) 150 (65.2) 135 (67.5) 123 (67.6) 12 (66.67) 
Age in years: median 
(IQR) 
32.8 (27.4-39.8) 32.7 (27.4-41.1) 32.9 (27.5-41.7) 28.6 (26.8-34.1) 
Height (cm): mean (sd) 164.0 (8.6) 163.9 (8.2) 163.9 (8.1) 163.8 (9.0) 
Weight (kg): median 
(IQR) 
67.3 (57.8-79.6) 68.1 (58.2-80.4)  68.2 (58.9-80.2) 63.1 (53.3-81.7) 
CD4 count: median 
(IQR) 
225 (133-287) 232.5 (143.5-287.5) 233 (145–287) 210 (129-308) 
Log HIV RNA 
(copies/ml): median 
(IQR) 
4.9 (4.4-5.4) 4.8 (4.4-5.4) 4.9 (4.8-5.4) 4.8 (4.5-5.4) 
HADS depression score 
of 8 or above: n (%) 
74 (32.1)  63 (31.5) 59 (32.4) 4 (22.2) 
HADS anxiety score of 8 
or above: n(%) 
89 (38.7)  76 (38) 70 (38.5) 6 (33.3) 
CAGE ≥2: n(%) 35 (15.2)  30 (15) 25 (13.7) 5 (27.8) 
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weighed less (63.1kg, IQR 53.3-81.7) and had more alcohol use (n=5, 27.8%), but neither difference 
reached significance.   
 















































Type of life event
Type & Frequency of Life Event experienced over 
a 48 week period
1-Personal - serious illness or injury, 2-Immediate family - serious illness or injury, 3-Other relatives or close friends - 
serious illness or injury, 4-Death -Immediate family, 5-Death -Other relatives or close friends, 6-Separated from 
partner, 7-Serious problem with a close friend, neighbour or relative, 8-You or immediate family been abused, 9-You 
or your partner been unemployed, 10-Fired or retrenched?, 11-Difficulty with debt, 12-You or your immediate family 
been burgled or mugged, 13-You been arrested by the police or been taken to court, 14-You or someone at home 
given birth, 15-Miscarriage / termination of pregnancy or still birth, 16-Moved house (your own decision), 17-Forced 
to move house, 18-Housing difficulties, 19-Other 
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Figure II. Number of Life events per category 
 
 
A total number of 353 life events were recorded, with a median of 1.0 event per person (IQR 0-
3).The most frequent individual events experienced were death in the immediate family (n=47, 
13.31%), unemployment (n=37, 10.48%), financial problems (n=30, 8.5%) and birth (n=28, 7.93%).  
The event categories most frequently experienced were work, including unemployment and debt 
problems (n=83, 23.5%); death (n=65, 18.4%); relationship problems, including separation and abuse 
(n=47, 13.3%); housing problems (n=42, 11.9%) and birth events including favourable and poor birth 
outcomes (n=39, 11.1%).   
Crude relationships between variables likely to impact on adherence and viral load were explored 
using the chi-square tests (Table II).   These showed individuals with depression were more likely to 
have poor adherence (n=14, 56%), however this association was not statistically significant (X2= 2.36, 
df=1, p=0.125).  No other significant differences were observed between the other covariates and 
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For virologic failure, the only statistically significant difference was noted between the age groups of 
younger and older than 30 years (X2=7.43, df=1, p=006), with younger people more likely to 
experience failure (Table II) . More females (n=14), fewer cases of depression (n=2, 8.0%) and 
anxiety (n=3, 8.1%); and no cases of alcohol use (n=0) were observed in people experiencing failure, 
but none met significance.   
 
Table II.  Chi-square test 
Table II Chi-square test:  Association between adherence or virologic suppression and covariates 









Females  60 (44.4) 75 (55.6) 135 0.4046 (1) 0.525 
Males  32 (49.2) 33 (50.8) 65 
Age 
Age <30 years  32 (45.7) 38 (54.3) 70 0.0035 (1) 0.953 
Age >30 years  60 (46.2) 70 (53.4) 130 
Alcohol use Yes 10 (45.5) 12 (54.5) 22 
0.1415 (1) 0.707 
  No 61 (41.2) 87 (58.8) 148 
Anxiety Yes 15 (40.5) 22 (59.5) 37 
0.0421 (1) 0.837 
  No 56 (42.4) 76 (57.6) 132 
Depression Yes 14 (56) 11 (44) 25 
2.3565 (1) 0.125 
  No 57 (39.6) 87 (60.4) 144 









Females  14 (11.4) 109 (88.6) 123 0.0599 (1) 0.807 
Males  6 (10.2) 53 (89.8) 59 
Age 
Age <30 years  12 (20) 48 (80) 60 7.4303 0.006 
Age >30 years  8 (6.6) 114 (93.4) 122 
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Alcohol use Yes 0 (0) 22 (100) 22 
2.2845 (1) 0.131 
  No 14 (9.5 133 (90.5) 147 
Anxiety Yes 3 (8.1) 34 (91.9) 37 
0.0032 (1) 0.955 
  No 11 (8.4) 120 (91.6) 131 
Depression Yes 2 (8.0) 23 (92.0) 25 
0.0043 (1) 0.948 
  No 12 (8.4) 131 (91.6) 143 
 
The total number of life events was significantly associated with virologic failure (OR 1.3, CI 1.06-1.6, 
p=0.011) but not with adherence (OR 1.09, CI 0.94-1.26; p=0.25) in univariate analysis.  One 
individual life event, poor birth outcomes, was significantly associated with both poor adherence 
(OR 5.7, CI 1.2-27.31, p=0.028) and virologic failure (OR 6.5, CI 1.66-25.47, p=0.007).  Regression 
analyses for all other individual life events were not significant; these data are not included here 
(available on request). 
The multivariate regression models for both adherence and viral suppression included potential 
confounding / moderating covariates such as: age, gender, alcohol use, anxiety and depression.  The 
results showed that the total number of events experienced had no significant association with poor 
adherence (aOR 1.13, CI 0.95-1.36, p=0.172) but came close to reaching significance for virologic 
failure (aOR 1.3, CI 0.97-1.75, p=0.077).  Poor birth outcomes showed significant associations both 
with poor adherence (aOR 6.45, CI 1.25-33.29, p=0.026) and virologic failure (aOR 8.88, CI 1.55-
50.58, p=0.014). 
Further results from the multivariate analyses (table III & IV), show that age is a protective factor for 
virologic failure. The odds of failure decreased significantly with every year of increase in age (aOR 
0.92, CI 0.85-0.99; p=0.048).  Depression had a marginally significant association with poor 
adherence when a poor birth outcome is experienced (aOR 2.58, CI 1.01-6.58, p=0.047). 
 
 




Table III.  The impact of the total number events on adherence or viral load 
*Alcohol use was omitted – no cases of alcohol use with virologic failure were present 
  
Table III. below presents odds ratios (OR) or adjusted odds ratios (aOR) with 95% confidence 
intervals (CI) for the impact of the total number events on adherence or viral load 
 
Univariate model Multivariate model 
Poor adherence (<80%) at week 48 OR (95% CI) 
p 
value OR (95% CI) 
p 
value 
Total number of events 1.09 (0.94-1.26) 0.251 1.13 (0.95-1.36) 0.172 
Age 0.99 (0.96-1.02) 0.576 0.98 (0.95-1.02) 0.421 
Gender 1.21 (0.67-2.19) 0.525 1.5 (0.75-3.14) 0.237 
Alcohol use 1.19 (0.48-2.93) 0.707 0.94 (0.36-2.50) 0.905 
Anxiety  0.93 (0.44-1.94) 0.837 0.64 (0.28-1.50) 0.306 
Depression 1.94 (0.82-4.5) 0.129 2.44 (0.97-6.13) 0.058 
Virologic failure (HIV RNA >50 copies/ ml) at week 48 *       
Total number of events 1.3 (1.06-1.60) 0.011 1.30 (0.97-1.75) 0.077 
Age 0.91 (0.85-0.97) 0.007 0.92 (0.85-0.99) 0.042 
Gender 0.88 (0.32-2.42) 0.807 2.01 (0.58-6.96) 0.267 
Anxiety  0.96 (0.25-3.64) 0.955 0.56 (0.11-2.81) 0.483 
Depression  0.95 (0.2-4.52) 0.948 1.36 (0.24-7.81) 0.725 
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Table IV.   The impact of the individual event, poor birth outcomes, with adherence or 
viral load 
Table IV. below presents odds ratios (OR) or adjusted odds ratios (aOR) with 95% confidence intervals 






Poor adherence (<80%) at week 48 OR (95% CI) p value OR (95% CI) p value 
Poor birth outcome 5.7 (1.2-27.31) 0.028 6.45 (1.25-33.29) 0.026 
Age 0.99 (0.96-1.02) 0.576 0.98 (0.95-1.02) 0.435 
Gender 1.21 (0.67-2.19) 0.525 1.6 (0.78-3.29) 0.194 
Alcohol use 1.19 (0.48-2.93) 0.707 1.03 (0.39-2.74) 0.956 
Anxiety  0.93 (0.44-1.94) 0.837 0.64 (0.27-1.49) 0.302 
Depression  1.94 (0.82-4.5) 0.129 2.58 (1.01-6.58) 0.047 
Virologic failure (HIV RNA>50 copies/ ml) at week 48 *       
Poor birth outcome 6.5 (1.66-25.47) 0.007 8.88 (1.56-50.58) 0.014 
Age 0.91 (0.85-0.97) 0.007 0.92 (0.85-0.99) 0.048 
Gender 0.88 (0.32-2.42) 0.807 2.89 (0.76-10.91) 0.118 
Anxiety  0.96 (0.25-3.64) 0.955 0.56 (0.11-2.82) 0.482 
Depression  0.95 (0.2-4.52) 0.948 1.29 (0.22-7.57) 0.781 




In our cohort of HIV-infected individuals in South Africa, who initiated ART and were followed over a 
48-week period, stressful life events, particularly death of a family member, unemployment, debt, 
birth and being a victim of crime were common. We found the experience of a higher number of life 
events was associated with a higher risk of virologic failure.  In our predominantly female cohort, 
individuals who experienced an adverse birth outcome were at higher risk of both poor adherence 
and virologic failure.  Individuals with depression emerged at increased risk of poor adherence when 
a poor birth outcome was experienced, and younger individuals were at increased risk of virologic 
failure when a higher number of life events or an adverse birth outcome was experienced.  In 
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contrast to other research, no associations were found between gender, depression, alcohol use and 
anxiety with ART adherence or virologic failure in our study. 
Our findings are consistent with other research which used a similar stressful life event (SLE) 
measurement and found that participants who experienced a higher number of SLEs were less likely 
to achieve optimal ART adherence, with increased odds of virologic failure (14, 23, 24).  Our findings 
add to the limited research in Africa on the impact of the number of SLEs on ART adherence and 
virologic failure (25).  A previous study demonstrated this association using a monthly measurement 
of SLEs and pill count-based adherence (14).  In our study, SLEs were measured using a long recall 
over a 48-week period and electronic adherence monitoring to provide a detailed, objective 
measurement.  This is an important finding as the high burden of SLEs in a challenging resource poor 
context has the potential to reduce the likelihood to adherence significantly and consequently, 
increase potential drug resistance and virologic failure (14, 16).  Our study findings did not show a 
significant association between the total number of events and poor adherence that would further 
explain the link to virologic failure.   
Adverse birth outcomes such as miscarriage, abortion and stillbirth have been previously linked to 
postpartum depression and anxiety with long-term psychological impact for some women (26, 27).  
Importantly, depression and anxiety have been widely demonstrated in the literature to be 
associated with higher risk of poor ART adherence and virologic failure. (28, 29).  Data from two 
recent South African studies, showed that pregnant women had lower adherence and more 
treatment interruptions; and the other study revealed that after ART initiation in pregnancy, 41% of 
postpartum women were not retained in care at 12 and 24- month follow up (30, 31).  Together, 
these findings emphasise the vulnerability of pregnant and postpartum women and the increasing 
need for interventions and support during routine care as well as targeted retention strategies 
 Strengths of this study include the objective electronic adherence monitoring, the availability of 
psychosocial metrics included in multivariable models and high retention of this cohort 
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(approximately 87%).  Limitations include: the missing data at week 48, resulting from missed visits 
in the parent study, which could have biased our study.  This missing data could be associated with 
higher depression, anxiety, alcohol use and virologic failure, thus the analysis could have either have 
underestimated or overestimated the actual association of SLEs with the psychosocial covariates, 
poor adherence and virologic failure.   Poor birth outcome data includes both individual and 
household responses and may not reflect an association between the individual’s experience and 
poor adherence or virologic failure.  The long recall period for the measurement of SLEs could be 
considered as another limitation of this study.  Poor recall could potentially have omitted some SLEs 
resulting in an underestimation of the number of SLEs and the frequency of individual life events. In 
addition, the duration of individual life events was not analysed and therefore, the cumulative effect 
of life events on adherence could not be determined.  The data could be further explored in future 
research to explain the relationship between the duration and cumulative effect of life events; and 
the mediating effect of covariates on the association between SLEs and adherence and virologic 
outcomes. 
Despite these limitations, this study provides evidence on the important implications of common 
SLEs on ART adherence and viral load among PLWH< highlighting the need to develop targeted 
interventions to alleviate and mitigate the psychological impact of SLEs.  Regular monitoring of SLEs 
and adherence has the potential to reduce the impact of SLEs and may improve the maintenance of 
good adherence.  Although, some SLEs are unavoidable, the impact could possibly be reduced 
through effective support resources of social workers or social welfare networks and interventions 
to teach or improve coping skills. 
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CONCLUSION 
SLEs are common in PLWH.  This study concludes that the number of SLEs experienced negatively 
impact viral suppression and thus, requires particular attention and awareness during clinical care.  
These data highlighted the need for more supportive strategies and differentiated care models for 
younger PLWH, pregnant and postpartum women to improve lifelong engagement in HIV care which 
is vitally important in optimizing overall health outcomes for PLWH.  
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PART D:  APPENDICES 
Appendix 1:  Recent Life Event (RLE) Questionnaire 
Date of visit dd - mmm - yyyy Patient number: ZZ 9999 
Please tick the EVENT OCURRED box if the event happened to you. 
Please note the month the event occurred 
Please tick the EVENT STILL AFFECTS YOU box if the event is still having an 









1. Have you had a serious illness or been injured?    
2. Has someone in your immediate family* had a serious illness or been 
injured? 
   
3. Have any of your other relatives or close friends had a serious illness 
or been injured? 
   
DEATH 
4. Has someone in your immediate family* died?    
5. Have any of your other relatives or close friends died?    
RELATION- 
SHIPS 
6. Have you separated from your partner (girl-or boy-friend, husband or 
wife)? 
   
7. Have you had a serious problem with a close friend, neighbour or 
relative? 
   
8. Have you, or an immediate family member been subject to any 
abuses (e.g. racial), attacks or threats? 
   
WORK 
9. Have you or your partner been unemployed or seeking work for 
>1month? 
   
10. Have you been fired or retrenched?    
11. Have you had difficulty paying your bills or paying off your debts?    
CRIME 
12. Have you or your immediate family been burgled or mugged?    
13. Have you been arrested by the police or been taken to court?    
BIRTH 
14. Have you or someone at home given birth?    
15. Have you or someone at home had a miscarriage / termination of 
pregnancy or still birth? 
   
HOUSING 
16. Have you moved house (your own decision)?    
17. Have you moved house (not your own choice)?    
18. Have you had any housing difficulties?    
OTHER 
19. Have you experienced any other significant event?  
Please specify:  ________________________________________ 
   
* Immediate family includes: mother, father, partner, sister, brother, children 
Completed by: Staff sign and date Checked by: Staff sign and date 
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Appendix 2:  Hospital Anxiety and Depression Score (HADS) Questionnaire 








No, not at 
all 
1. I wake early and then sleep badly for the rest of the
night. 
3 2 1 0 
2. I get very frightened or have panic feelings for
apparently no reason at all. 
3 2 1 0 
3. I feel miserable and sad. 3 2 1 0 
4. I feel anxious when I go out of the house on my own. 3 2 1 0 
5. I have lost interest in things. 3 2 1 0 
6. I get palpitations, or sensations of ‘butterflies’ in my
stomach or chest. 
3 2 1 0 
7. I have a good appetite. 0 1 2 3 
8. I feel scared or frightened. 3 2 1 0 
9. I feel life is not worth living. 3 2 1 0 
10. I still enjoy the things I used to. 0 1 2 3 
11. I am restless and can’t keep still. 3 2 1 0 
12. I am more irritable than usual. 3 2 1 0 
13. I feel as if I have slowed down. 3 2 1 0 
14. Worrying thoughts constantly go through my mind. 3 2 1 0 
Add the scores for anxiety and depression: 
• Anxiety 2, 4, 6, 8, 11, 12, 14: Total _________________
• Depression 1, 3, 5, 7, 9, 10, 13 Total _________________ 
GRADING: 0 - 7 = Non-case 8 – 10 = Borderline case 11+ = Case 
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Appendix 3:  CAGE Questionnaire 
 
Date:  dd - mmm - yyyy Patient number: ZZ 9999 
 
CAGE questionnaire. 
Ask the following questions: 
1. Have you ever felt you needed to Cut down on your drinking? Yes   □ No   □ 
2. Have people Annoyed you by criticizing your drinking?   Yes   □ No   □ 
3. Have you ever felt Guilty about drinking?     Yes   □ No   □ 
4. Have you ever felt you needed a drink first thing in the morning (Eye-opener) to 
steady your nerves or to get rid of a hangover?    Yes   □ No   □ 
 
Each YES = 1 point. Write SCORE (1-4) here and on questionnaire CRF:  SCORE: _______ 
 
[Two "yes" responses indicate that the possibility of alcoholism should be investigated 
further → place copy of this from in Hannan folder.] 
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Appendix 4:  University of Cape Town HREC approval: Recent Life Event Questionnaire 
Signature Removed
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Appendix 5:  University of Cape Town HREC approval letter 
Signature Removed
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Appendix 6:  AIDS & Behavior Manuscript instructions 
Manuscript Preparation 
• Type double-spaced on one side of 8 ½ × 11-inch white paper using generous margins
on all sides, (including copies of all illustrations and tables).
• A title page is to be provided and should include the title of the article, authors name
(no degrees), authors affiliation, and suggested running head. The affiliation should
comprise the department, institution (usually university or company), city, and state
(or nation) and should be typed as a footnote to the authors name. The suggested
running head should be less than 80 characters (including spaces) and should
comprise the article title or an abbreviated version thereof. For office purposes, the
title page should include the complete mailing address, telephone number, fax
number, and email address of the one author designated to review proofs.
• With the exception of Brief Reports and Behavioral Surveillance Reports, initial
submissions to AIDS and Behavior do not have word or page limits. Briefer and more
succinct papers tend to review better and papers may be reduced in length as part of
the review process. However, the length of the original submission is left to author
discretion.
• An abstract is to be provided, preferably no longer than 150 words.
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• A list of 4-5 key words is to be provided directly below the abstract. Key words
should express the precise content of the manuscript, as they are used for indexing
purposes.
• All sections should carry headings (such as INTRODUCTION, METHODS,
RESULTS, DISCUSSION, CONCLUSIONS, etc.), typed flush left. All
acknowledgments (including those for grant and financial support) should be typed in
one paragraph (so−headed) on a separate page, that directly precedes the References
section.
• Illustrations (photographs, drawings, diagrams, and charts) are to be numbered in one
consecutive series of Arabic numerals. The captions for illustrations should be typed
on a separate sheet of paper. All illustrations must be complete and final, i.e., camera-
ready. Photographs should be large, glossy prints, showing high contrast. Drawings
should be high quality laser prints or should be prepared with india ink. Either the
original drawings or good−quality photographic prints are acceptable. Artwork for
each figure should be provided on a separate sheet of paper. Identify figures on the
back with authors name and number of the illustration. Electronic artwork submitted
on disk should be in the TIFF or EPS format (1200 dpi for line and 300 dpi for
halftones and grayscale art). Color art should be in the CYMK color space. Artwork
should be on a separate disk from the text, and hard copy must accompany the disk.
• Tables should be numbered (with Roman numerals) and referred to by number in the
text. Each table should be typed on a separate sheet of paper. Center the title above
the table and type explanatory footnotes (indicated by superscript lowercase letters)
below the table.
• AIDS and Behavior does not have a limit on number of authors. However, if deemed
to be excessive the editor may request author justifications and reductions.
AIDS and Behavior uses Vancouver style as outlined in the American Medical Association 
Manual of style: A Guide for Authors and Editors, 10th Edition. 
A reference number is allocated to a source in the order in which it is cited in the text. In text, 
identify references as Arabic numerals in brackets (1). If the source is referred to again, the 
same number is used. References are listed in numerical order in the Reference List at the end 
of the paper. Do not alphabetize. Use abbreviated names of journals according to the journal 
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